Neola Medical (NEOLA) Q2 2026 earnings summary

Executive summary

• Completed first clinical pilot study in preterm babies, confirming a favorable safety profile and supporting further development for U.S. and European markets.

• Raised approximately SEK 32.5 million through a rights issue, subscribed to about 70%, to support clinical, regulatory, and market preparation activities.

• Sharpened strategic focus towards continuous lung monitoring and detection of potentially life-threatening lung collapse, aiming to provide significant clinical value in neonatal intensive care.

• Granted a U.S. patent for reducing optical noise in lung monitoring, strengthening IP protection in a key market; also granted in China and pending in Europe.

• Business model centers on device sales, recurring disposable probe revenues, and service agreements, targeting leading U.S. neonatal intensive care units for initial commercialization.

Financial highlights

• Operating revenue for January–June 2026 was SEK 6,193k, up from SEK 4,381k year-over-year, mainly from capitalized development work.

• Q2 2026 operating result: -SEK 3.7 million (vs. -SEK 3 million Q2 2025); first half 2026 operating result: -SEK 7.3 million (vs. -SEK 5.7 million H1 2025).

• Cash flow for January–June 2026: -SEK 12.1 million (vs. SEK 6.96 million H1 2025); cash and cash equivalents at SEK 4,031k at period end.

• Equity ratio at 93% (vs. 95% year-over-year), with no interest-bearing debt.

• Monthly burn rate increased to SEK 2.0 million (from SEK 1.8 million), expected to rise further as clinical and regulatory work accelerates.

Outlook and guidance

• Preparing for U.S. regulatory pathway, including preclinical validation and FDA interactions, with a U.S. clinical study targeted for mid-2027.

• Proceeds from the rights issue will fund continued development, validation studies, regulatory activities, and commercial preparations.

• Cost base and burn rate expected to increase due to expanded clinical and regulatory activities.

• Focus for H2 2026: preclinical validation, FDA progress, and U.S. clinical study design.